This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zhang, L. Articles by Rosin, M. P. Search for Related Content PubMed PubMed Citation Articles by Zhang, L. Articles by Rosin, M. P. Related Collections Risk Assessment Risk Assessment: Biomarkers

Toluidine Blue Staining Identifies High-Risk Primary Oral Premalignant Lesions with Poor Outcome

¹ Faculty of Dentistry, University of British Columbia; ² BC Cancer Agency/Cancer Research Centre; ³ School of Kinesiology, Simon Fraser University; and ⁴ Vancouver Hospital and Health Sciences Centre, Vancouver, British Columbia, Canada

Requests for reprints: Miriam P. Rosin, Cancer Control Research Program, British Columbia Cancer Research Centre, Room 3-113, 675 West 10th Avenue, Vancouver, British Columbia, Canada V5Z 1L3. Phone: 604-675-8078; Fax: 604-675-8180; E-mail: Miriam_Rosin{at}shaw.ca.

There is a pressing need for the development of visual aids that will facilitate the detection of oral premalignant lesions (OPLs) with a high-risk of progression. Preliminary data suggest that toluidine blue stain may be preferentially retained by OPLs with high-risk molecular clones. In this study, we monitored OPLs from 100 patients without any history of oral cancer for an average of 44 months in order to evaluate the association of toluidine blue status with clinicopathologic risk factors, molecular patterns (microsatellite analysis on seven chromosome arms: 3p, 9p, 4q, 8p, 11q, 13q, and 17p) and outcome. Toluidine blue–positive staining correlated with clinicopathologic risk factors and high-risk molecular risk patterns. Significantly, a >6-fold elevation in cancer risk was observed for toluidine blue–positive lesions, with positive retention of the dye present in 12 of the 15 lesions that later progressed to cancer (P = 0.0008). This association of toluidine blue status with risk factors and outcome was evident even when the analysis was restricted to OPLs with low-grade or no dysplasia. Our results suggest the potential use of toluidine blue in identifying high-risk OPLs.

This article has been cited by other articles:

				L. L. Patton, J. B. Epstein, and A. R. Kerr Adjunctive Techniques for Oral Cancer Examination and Lesion Diagnosis: A Systematic Review of the Literature J Am Dent Assoc, July 1, 2008; 139(7): 896 - 905. [Abstract] [Full Text] [PDF]

				A. B Glick The High Risk Premalignant Lesion: Experimental Evidence and Clinical Implications Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 513 - 516. [Abstract] [Full Text] [PDF]

				J. B. Epstein, M. Gorsky, D. Fischer, A. Gupta, M. Epstein, and S. Elad A Survey of the Current Approaches to Diagnosis and Management of Oral Premalignant Lesions J Am Dent Assoc, December 1, 2007; 138(12): 1555 - 1562. [Abstract] [Full Text] [PDF]

				W. H. Westra and D. Sidransky Fluorescence Visualization in Oral Neoplasia: Shedding Light on an Old Problem. Clin. Cancer Res., November 15, 2006; 12(22): 6594 - 6597. [Full Text] [PDF]

				C. F. Poh, L. Zhang, D. W. Anderson, J. S. Durham, P. M. Williams, R. W. Priddy, K. W. Berean, S. Ng, O. L. Tseng, C. MacAulay, et al. Fluorescence Visualization Detection of Field Alterations in Tumor Margins of Oral Cancer Patients. Clin. Cancer Res., November 15, 2006; 12(22): 6716 - 6722. [Abstract] [Full Text] [PDF]

				N. K. Proia, G. M. Paszkiewicz, M. A. Sullivan Nasca, G. E. Franke, and J. L. Pauly Smoking and smokeless tobacco-associated human buccal cell mutations and their association with oral cancer--a review. Cancer Epidemiol. Biomarkers Prev., June 1, 2006; 15(6): 1061 - 1077. [Abstract] [Full Text] [PDF]

				B Perez-Ordonez, M Beauchemin, and R C K Jordan Molecular biology of squamous cell carcinoma of the head and neck. J. Clin. Pathol., May 1, 2006; 59(5): 445 - 453. [Abstract] [Full Text] [PDF]

				S. M. Lippman and J. J. Lee Reducing the "Risk" of Chemoprevention: Defining and Targeting High Risk--2005 AACR Cancer Research and Prevention Foundation Award Lecture. Cancer Res., March 15, 2006; 66(6): 2893 - 2903. [Abstract] [Full Text] [PDF]